Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Junior Gold Miners (GDXJ) vs McKesson Corporation (MCK) Price & Performance

VanEck Junior Gold MinersTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

VanEck Junior Gold Miners vs McKesson Corporation — how do they compare? VanEck Junior Gold Miners trades at $114.41 (market cap $8.22B), while McKesson Corporation trades at $941.58 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 13.2× VanEck Junior Gold Miners's market cap, and McKesson Corporation pays a 0.4% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and McKesson Corporation for 74 Days on average.

GDXJMCK
Market Cap
$8.22B$108.46B
Volume
3,212,198712,607
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$156.19$995.69
52-Week Low
$87.56$725.17
Typical Hold Time
41 Days74 Days
Enterprise Value
—$115.00B
Dividend Yield
—0.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Junior Gold Miners

GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.

The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.

McKesson Corporation

McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.

The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GDXJ
100% Buy0% Sell
Avg holding period · 41 Days
MCK
100% Buy0% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About VanEck Junior Gold Miners

GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.

Read more on GDXJ →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →